Hookipa Pharma Inc. (HOOK)

$2.79

-0.01

(-0.36%)▲

Market is closed - opens 8 PM, 20 Nov 2024

Performance

  • $2.70
    $2.98
    $2.79
    downward going graph

    3.23%

    Downside

    Day's Volatility :9.46%

    Upside

    6.44%

    downward going graph
  • $2.70
    $11.30
    $2.79
    downward going graph

    3.23%

    Downside

    52 Weeks Volatility :76.11%

    Upside

    75.31%

    downward going graph

Returns

PeriodHookipa Pharma Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-44.09%
-8.6%
0.0%
6 Months
-67.52%
-3.3%
0.0%
1 Year
-44.97%
9.4%
0.0%
3 Years
-92.01%
6.2%
-24.5%

Highlights

Market Capitalization
36.2M
Book Value
$7.45
Earnings Per Share (EPS)
-4.12
Wall Street Target Price
43.0
Profit Margin
-93.16%
Operating Margin TTM
-1736.74%
Return On Assets TTM
-20.1%
Return On Equity TTM
-48.99%
Revenue TTM
52.2M
Revenue Per Share TTM
4.4
Quarterly Revenue Growth YOY
-51.800000000000004%
Gross Profit TTM
-53.0M
EBITDA
-47.7M
Diluted Eps TTM
-4.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.62
EPS Estimate Next Year
-7.7
EPS Estimate Current Quarter
-1.9
EPS Estimate Next Quarter
-1.6

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Hookipa Pharma Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1441.22%

Current $2.79
Target $43.00

Company Financials

FY18Y/Y Change
Revenue
7.6M
-
Net Income
-16.2M
↑ 27.62%
Net Profit Margin
-212.83%
-
FY19Y/Y Change
Revenue
11.9M
↑ 56.53%
Net Income
-34.1M
↑ 110.3%
Net Profit Margin
-285.94%
↓ 73.11%
FY20Y/Y Change
Revenue
19.6M
↑ 63.99%
Net Income
-33.8M
↓ 1.01%
Net Profit Margin
-172.59%
↑ 113.35%
FY21Y/Y Change
Revenue
18.4M
↓ 5.8%
Net Income
-75.7M
↑ 123.86%
Net Profit Margin
-410.16%
↓ 237.57%
FY22Y/Y Change
Revenue
14.2M
↓ 22.76%
Net Income
-65.1M
↓ 13.9%
Net Profit Margin
-457.19%
↓ 47.03%
FY23Y/Y Change
Revenue
20.1M
↑ 41.27%
Net Income
-81.6M
↑ 25.23%
Net Profit Margin
-405.29%
↑ 51.9%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 15.65%
Net Income
-18.0M
↓ 9.4%
Net Profit Margin
-672.49%
↓ 46.39%
Q3 FY23Q/Q Change
Revenue
6.9M
↑ 156.33%
Net Income
-19.1M
↑ 5.83%
Net Profit Margin
-277.65%
↑ 394.84%
Q4 FY23Q/Q Change
Revenue
7.4M
↑ 7.86%
Net Income
-24.8M
↑ 30.17%
Net Profit Margin
-335.06%
↓ 57.41%
Q1 FY24Q/Q Change
Revenue
36.6M
↑ 394.11%
Net Income
14.4M
↓ 157.95%
Net Profit Margin
39.3%
↑ 374.36%
Q2 FY24Q/Q Change
Revenue
1.3M
↓ 96.48%
Net Income
-19.1M
↓ 232.76%
Net Profit Margin
-1.5K%
↓ 1519.53%
FY18Y/Y Change
Total Assets
68.3M
↓ 7.43%
Total Liabilities
23.9M
↓ 79.51%
FY19Y/Y Change
Total Assets
143.7M
↑ 110.61%
Total Liabilities
25.8M
↑ 8.36%
FY20Y/Y Change
Total Assets
187.8M
↑ 30.66%
Total Liabilities
31.7M
↑ 22.63%
FY21Y/Y Change
Total Assets
126.0M
↓ 32.89%
Total Liabilities
36.5M
↑ 15.02%
FY22Y/Y Change
Total Assets
170.5M
↑ 35.23%
Total Liabilities
67.9M
↑ 86.37%
FY23Y/Y Change
Total Assets
161.3M
↓ 5.35%
Total Liabilities
71.5M
↑ 5.22%
Q2 FY23Q/Q Change
Total Assets
191.1M
↑ 17.18%
Total Liabilities
78.8M
↓ 1.04%
Q3 FY23Q/Q Change
Total Assets
164.0M
↓ 14.18%
Total Liabilities
69.0M
↓ 12.47%
Q4 FY23Q/Q Change
Total Assets
161.3M
↓ 1.63%
Total Liabilities
71.5M
↑ 3.66%
Q1 FY24Q/Q Change
Total Assets
145.9M
↓ 9.59%
Total Liabilities
41.3M
↓ 42.15%
Q2 FY24Q/Q Change
Total Assets
125.0M
↓ 14.28%
Total Liabilities
39.0M
↓ 5.72%
Q3 FY24Q/Q Change
Total Assets
109.7M
↓ 12.25%
Total Liabilities
37.9M
↓ 2.7%
FY18Y/Y Change
Operating Cash Flow
-15.0M
↑ 25.9%
Investing Cash Flow
-2.2M
↑ 65.77%
Financing Cash Flow
6.9M
↓ 88.33%
FY19Y/Y Change
Operating Cash Flow
-41.7M
↑ 178.24%
Investing Cash Flow
-2.0M
↓ 7.02%
Financing Cash Flow
109.8M
↑ 1496.84%
FY20Y/Y Change
Operating Cash Flow
-39.3M
↓ 5.73%
Investing Cash Flow
-2.4M
↑ 18.61%
Financing Cash Flow
73.4M
↓ 33.1%
FY21Y/Y Change
Operating Cash Flow
-66.0M
↑ 67.81%
Investing Cash Flow
-12.6M
↑ 430.62%
Financing Cash Flow
-235.0K
↓ 100.32%
FY22Y/Y Change
Operating Cash Flow
-20.0M
↓ 69.71%
Investing Cash Flow
-5.0M
↓ 60.12%
Financing Cash Flow
72.3M
↓ 30853.62%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.3M
↑ 578.83%
Investing Cash Flow
-445.0K
↑ 62.41%
Financing Cash Flow
45.8M
↓ 6333.33%

Technicals Summary

Sell

Neutral

Buy

Hookipa Pharma Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hookipa Pharma Inc.
Hookipa Pharma Inc.
-30.08%
-67.52%
-44.97%
-92.01%
-96.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.12%
-24.58%
-7.12%
15.69%
116.3%
Biontech Se
Biontech Se
-4.64%
15.06%
7.66%
-66.93%
422.85%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-19.77%
55.93%
41.76%
25.27%
116.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.29%
0.48%
25.55%
146.84%
108.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hookipa Pharma Inc.
Hookipa Pharma Inc.
NA
NA
NA
-2.62
-0.49
-0.2
NA
7.45
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.02
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hookipa Pharma Inc.
Hookipa Pharma Inc.
Buy
$36.2M
-96.66%
NA
-93.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
116.3%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
422.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
116.5%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
108.31%
32.84
-4.51%

Insights on Hookipa Pharma Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 36.59M → 1.29M (in $), with an average decrease of 96.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -19.09M → -13.84M (in $), with an average increase of 38.0% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 41.8% return, outperforming this stock by 86.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 29.4% return, outperforming this stock by 121.5%

Institutional Holdings

  • Baker Bros Advisors LP

    8.21%

  • EcoR1 Capital, LLC

    5.78%

  • Artal Group S A

    5.73%

  • Knoll Capital Management LP

    5.58%

  • FMR Inc

    3.45%

  • Vanguard Group Inc

    2.15%

Company Information

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a

Organization
Hookipa Pharma Inc.
Employees
151
CEO
Dr. Malte Peters M.D.
Industry
Pharmaceuticals: Major

FAQs